Find → Understand → Decide
24 IU intranasal Oxytocin
Discovery priority: LOW · POSSIBLE / INVESTIGATE
Discovery priority ≠ investment recommendation. These are observation labels, not verified canonical products. Buyer qualification: UNKNOWN.
Why investigate?
Why stranded (event context): supply failure
Why now: Historical lead requires current reconfirmation; no fresh transaction catalyst established
Company/trial failed before biology? UNKNOWN
Biology implicated: UNCLEAR · Failure context: CMC/OPERATIONS
MODEL INFERENCE · LOW confidence. Explicit asset-linked program event or documented experimental trial arm, stop scope, dated recency and biological cautions; no publication count or buyer-gate input.
Current control: UNKNOWN · Restart: UNKNOWN · Development reuse: UNKNOWN
Next diligence: Confirm present program status and exact product identity, then trace scoped rights/data/CMC and review arm-level human outcomes.
Existing buyer gates
Human Signal: UNKNOWN
Cheap Truth: UNKNOWN
Clean Rights: UNKNOWN
Market Pull: UNKNOWN
No event or publication count supplies missing gate evidence. Existing reviewed opportunities remain in their original records.
Evidence timeline
2026-07-02 · trial:NCT02225600
Registry update date, not proven program-stop date
SOURCE TEXT · Exact source
Study was halted during COVID pandemic. However, PI is currently reconnecting with a compounding pharmacy to re-establish supply of the oxytocin and updating cost estimates. We are hoping to resume the pilot work with oxytocin once it is clarified.
Trial reason is not attributed to every intervention; comparator/combination context needs review.
Interpretation: supply failure · AUTO_INFERRED · MEDIUM
Provenance and retrieval scope
{
"hash": "92f13dc8127b87be76fb46c8a1db11ee415dba0b87a76131c19dfff07688c6d8",
"metadata": {
"complete": false,
"content_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"failed": false,
"last_checked": 1790026984.0751398,
"last_success": 1790026984.0751398,
"live_verified": true,
"scope": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)"
},
"path": "protocolSection.armsInterventionsModule.interventions",
"raw_hash": "38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e",
"raw_path": "research/obz7_sources/38a1f6b0acab83e32f1bc4be6780a423f51adefad10b1134fa1db1296649450e.json",
"request_params": {
"countTotal": "true",
"format": "json",
"pageSize": 100,
"query.term": "AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL)",
"sort": "LastUpdatePostDate:desc"
},
"request_url": "https://clinicaltrials.gov/api/v2/studies",
"type": "clinicaltrials",
"url": "https://clinicaltrials.gov/study/NCT02225600"
}Freshness is claim-specific
Fetching an old filing today does not establish current ownership or program status.
pipeline · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
sec · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
rights · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
contact · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
patent_assignment · PARTIAL · Not independently refreshed for current scoped claim · checked UNKNOWN
clinicaltrials · STALE · AREA[OverallStatus]SUSPENDED AND AREA[StartDate]RANGE[2000-01-01,2014-12-31] AND (AREA[InterventionType]DRUG OR AREA[InterventionType]BIOLOGICAL) · checked 2026-09-21T21:43:04.075140+00:00
Registry observations (1)
NCT02225600 · SUSPENDED · NA · Borderline Personality Disorder · Trial sponsor Icahn School of Medicine at Mount Sinai
Reported aliases: syntocin; OT. Identity, treatment role and exposure require review.